Efficacy and Safety of Segmental Resection Combined With the DEP Regimen for Epstein-Barr Virus Associated Hemophagocytic Lymphohistiocytosis With Intestinal Involvement
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- ORR
研究概览
简要总结
EBV-HLH is a rare disease with high mortality, especially for those with intestinal involvement. In order to reduce disease burden and improve survival of these patients, we conduct a prospective observational study to explore the efficacy and safety of segmental resection combined with the DEP regimen.
详细描述
Epstein-Barr virus associated hemophagocytic lymphohistiocytosis is a rare disease with high mortality, especially for those with intestinal involvement. Some of them still died despite early control of the disease due to severe complications, such as gastrointestinal bleeding. In order to reduce disease burden and improve survival of these patients, we conduct a prospective observational study to explore the efficacy and safety of segmental resection combined with the DEP regimen.
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Met HLH-2004 diagnostic criteria;
- •EBV-DNA in the peripheral blood > 1000 copies/ml or EBV-encoded small RNA (EBER) detected in tissues;
- •Imaging revealed severe intestinal lesions and biopsy confirmed EBV-encoded small RNA (EBER) in the tissues;
- •Age >18 years old, gender is not limited;
- •Estimated survival time > 1 month;
- •Informed consent obtained.
排除标准
- •Active infections (viral, bacterial, fungal or parasitic);
- •Diagosed with malignant tumos within 5 years；
- •Uncontrolled symptoms or other diseases including, but not limited to, unstable angina pectoris, arrhythmia, respiratory failure, severe hepatic or renal insufficiency, severe coagulation dysfunction, mental illness, or other conditions deemed by the attending physician to be contraindications to surgery;
- •Heart function above grade II (NYHA);
- •Severe myocardial injury：TNT、TNI、CK-MB > 3 ULN;
- •Accumulated dose of doxorubicin above 400mg/m2 、epirubicin above 750mg/m2、pirarubicin above 800mg/m2 or the patients treated with anthracycline induced cardiovascular disease;
- •Pregnancy or lactating Women;
- •Allergic to pegylated liposomal doxorubicin and etoposide;
- •HIV antibody positivity;
- •Acute or chronic active hepatitis B (HBsAg positivity, HBV DNA negative acceptable), acute or chronic active hepatitis C (HCV antibody negatively acceptable; HCV antibody positivity, HCV RNA negative acceptable);
- •Participate in other clinical research at the same time;
- •The researchers considered that patients are not suitable for the study.
结局指标
主要结局
ORR
时间窗: 4 Week
The percentage of cases that achieved complete response (CR) and partial response (PR) after treatment.
Adverse events
时间窗: 1 month
Incidence of adverse reactions
次要结局
- OS(1 years)
研究者
Zhao Wang
Professor and Head of hematology
Beijing Friendship Hospital